• Richard D Berkowitz, Richard Steinfeld, Alexander P Sah, Vamshi Ruthwik Anupindi, Drishti Shah, Mitch DeKoven, Katharine Coyle, Stewart W McCallum, Randall Mack, Erin Coyle, Alex Freyer, Wei Du, and Libby K Black.
• Richard D. Berkowitz, MD, FAAOS is with University Orthopedic and Joint Replacement Center, University Hospital, Tamarac, FL.
• J Pain Palliat Care Pharmacother. 2021 Sep 1; 35 (3): 150-162.

AbstractWe evaluated the economic impact associated with preoperative meloxicam IV 30 mg vs placebo administration among adult total knee arthroplasty (TKA) recipients enrolled in Phase IIIB NCT03434275 trial. Data on total hospital costs and length of stay (LOS) obtained from the trial were compared between meloxicam IV 30 mg and placebo groups. Patients in the meloxicam IV 30 mg vs placebo group (n = 93 vs 88) incurred an adjusted $2,266 (95% CI: -$1,035, $5,116; p = 0.1689) lower total hospital costs and an adjusted 8.6% (95% confidence interval [CI]: -2.0%, 18.1%; p = 0.1082) shorter LOS. While statistically non-significant, based on 95% CIs, the results from this sub-study may suggest a favorable impact associated with meloxicam IV 30 mg on hospital costs and LOS.

12 keywords...

hide…